Gene Therapy - A New Era of Medicine
Katherine High, Spark Therapeutics
October 18, 2016 | EmTech
Gene Therapy: A New Era of Medicine
Katherine High, Cofounder, President and Chief Scientific Officer, Spark Therapeutics
Katherine High, a world renowned hematologist, began her career studying the molecular basis of blood coagulation and the development of novel therapeutics for the treatment of bleeding disorders. Her pioneering bench-to-bedside studies of gene therapy for hemophilia led to a series of studies that characterized the human immune response to adeno-associated virus vectors in a variety of target tissues. High’s work has evolved to encompass clinical translation of genetic therapies for multiple inherited disorders. As the director of the Center for Cellular and Molecular Therapeutics at the Children’s Hospital of Philadelphia, High assembled a multidisciplinary team of scientists and researchers working to discover new gene and cell therapies for genetic diseases and to facilitate rapid translation of preclinical discoveries into clinical application. High served a five-year term on the FDA Advisory Committee on Cell, Tissue and Gene Therapies and is a past president of the American Society of Gene & Cell Therapy. She received her A.B. in chemistry from Harvard University, an M.D. from the University of North Carolina School of Medicine, business certification from the UNC Business School Management Institute for Hospital Administrators, and a master’s degree from the University of Pennsylvania.
Reprogramming our bodies to make us healthier.
Please enter your email address to view this free video.
We'd like to keep in touch about future MIT Technology Review initiatives and events.